Mental Health

First Opinion Michael Alvear

I analyzed 6 months of Reddit discussion about at-home ketamine therapy. The findings alarmed me

First Opinion Debra Manetta

I had a brother with schizophrenia. I can’t stop thinking about Nick Reiner’s siblings

Biotech Elaine Chen

STAT Plus: Compass says its psilocybin drug helped patients with severe depression in two trials

Health tech Mario Aguilar

STAT Plus: Talkiatry raises $210 million, eyeing opportunity to use AI for engaging with patients

Health tech Mario Aguilar

STAT Plus: Big Health raises funding as investors see glimmer of hope for digital therapeutics

First Opinion Harvey Lieberman

How AI is making me a better clinical psychologist

First Opinion Henry I. Miller

Dogs might be the secret to getting some anxious patients in the dentist’s chair

Health Lev Facher

Trump administration reverses course on $1.9 billion in cuts to addiction and mental health grants

First Opinion Stephen B. Soumerai and Christine Y. Lu

RFK Jr.’s war on antidepressants is coming — and it will cost lives

Health Lev Facher

3 drug policy questions to watch in 2026

Health Eric Berger

For some with bipolar disorder, manic episodes are magnified for all to see online

Health Olivia Rockeman

A promising method for suicide prevention starts in the doctor’s office

First Opinion Venktesh Ramnath

When a doctor can’t heal his friends

Health tech Mario Aguilar

STAT Plus: Boehringer Ingelheim prepares schizophrenia app for FDA submission after trial results

The Readout LOUD Elaine Chen, Adam Feuerstein, and Allison DeAngelis

A new top drug regulator and the future of psychedelics

First Opinion Miranda Wolpert

The overdiagnosis debate in mental health misses the point

Health tech O. Rose Broderick

STAT Plus: Why first-generation mental health apps cannot ignore next-gen AI chatbots

Health tech Mario Aguilar

STAT Plus: Is Slingshot’s mental health chatbot safe? Its first study raises questions about evaluating AI

Pharmalot Ed Silverman

STAT Plus: Pfizer and Tris agree to $41.5 million settlement with Texas over ADHD drug for children

First Opinion Ellen Hengesbach

I spent two hours telling a chatbot about mental health problems. Its responses scared me

First Opinion Khutaija Noor

STAT Plus: The era of safe bets in psychiatric medicine is over

First Opinion Isaac Rose-Berman

The rise of sports betting is a growing public health crisis

Pharma Damian Garde

STAT Plus: FDA approves J&J’s antipsychotic drug to treat depression

Health tech Mario Aguilar

STAT Plus: FDA digital advisers confront risks of therapy chatbots, weigh possible regulation

Biotech Elaine Chen

STAT Plus: Compass Pathways expects earlier FDA approval decision on its psilocybin drug

First Opinion Steve Ramirez

I’m a neuroscientist who works on memory manipulation. My work helps me recover from addiction

First Opinion Harvey Lieberman

The right place for AI companions in mental health care

Politics O. Rose Broderick and Lev Facher

STAT Plus: Trump cuts have decimated the federal addiction and mental health agency

First Opinion Valerie Black

STAT Plus: ‘AI psychosis’ discussions ignore a bigger problem with chatbots